The Organic Selenium Compound Selenomethionine Modulates Bleomycin-Induced DNA Damage and Repair in Human Leukocytes
- 210 Downloads
The objective of this work was to evaluate the effects of selenomethionine (SeMet) on the induction, repair, and persistence of DNA damage in human leukocytes challenged with bleomycin (BLM). Comet assay was used to determine DNA strand breaks and hOGG1 for the specific recognition of oxidative damage. Leukocytes were (A) stimulated with phytohemagglutinin, (B) damaged with BLM, and (C) incubated to allow DNA repair. Comet assay was performed after each phase. SeMet (50 μM) was supplemented either during phase A, B, or C, or AB, or ABC. Treatment with SeMet decreased BLM-induced stand breaks when added during phase AB. Results obtained after the repair period indicate that SeMet favors repair of DNA damage especially when applied during phase AB. The comparison between DNA damage before and after repair showed that BLM-induced damage was repaired better in the presence of SeMet. Our results showed antigenotoxic effect of SeMet on BLM-induced DNA and also on repair and persistence of this damage when applied before and simultaneously with BLM.
KeywordsSelenomethionine Bleomycin Comet assay Oxidative damage Antigenotoxicity
This work was funded by a grant from the Xunta de Galicia (INCITE08PXIB106155PR). V. Valdiglesias was supported by a fellowship from the University of A Coruña.
- 5.Gajecka M, Rydzanicz M, Jaskula-Sztul R, Wierzbicka M, Szyfter W, Szyfter K (2005) Reduced DNA repair capacity in laryngeal cancer subjects. Curr Res Head Neck Cancer 62:25–37Google Scholar
- 24.Rao M, Kamath R, Rao MNA (1998) Protective effect of selenomethionine against cisplatin-induced nephrotoxicity in C57BL76J mice bearing B16F1 melanoma without reducing antitumour activity. Pharm Pharmacol Commun 4:549–552Google Scholar
- 32.Kim Y-J, Baek SH, Bogner PN, Ip C, Rustum YM, Fakih MG, Ramnath N, Park YM (2007) Targeting the Nrf2-Prx1 pathway with selenium to enhance the efficacy and selectivity of cancer therapy. J Cancer Mol 3:37–43Google Scholar